Wells' syndrome (eosinophilic cellulitis) secondary to infliximab.
Nicola
N
Tugnet
Amgad
A
Youssef
Andrew J
AJ
Whallett
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D002481:Cellulitis / Q000139:chemically induced*; D003875:Drug Eruptions / Q000209:etiology*; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab